

Werner J Heinz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6144344/publications.pdf>

Version: 2024-02-01

70
papers

4,389
citations

145106

33
h-index

134545

62
g-index

74
all docs

74
docs citations

74
times ranked

4613
citing authors

#	ARTICLE	IF	CITATIONS
1	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. <i>Haematologica</i> , 2021, 106, 543-554.	1.7	12
2	State of Medical Mycology at German Academic Medical Centres: A Survey of the German-Speaking Mycological Society (DMYKG) and the Paul Ehrlich-Society for Chemotherapy (PEG). <i>Mycoses</i> , 2021, 64, 1177-1182.	1.8	0
3	Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia. <i>Mycoses</i> , 2020, 63, 1101-1106.	1.8	6
4	Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Mycoses</i> , 2020, 63, 653-682.	1.8	42
5	Comment on: T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 532-533.	1.3	3
6	Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 56-61.	1.2	2
7	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3315-3327.	1.3	30
8	Aspergillus-specific nested PCR from the site of infection is superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis. <i>Mycoses</i> , 2019, 62, 1035-1042.	1.8	7
9	Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals. <i>International Journal of Infectious Diseases</i> , 2019, 83, 130-138.	1.5	10
10	Diagnostic work up to assess early response indicators in invasive pulmonary aspergillosis in adult patients with haematologic malignancies. <i>Mycoses</i> , 2019, 62, 486-493.	1.8	16
11	A Comparison of Aspergillus and Mucorales PCR Testing of Different Bronchoalveolar Lavage Fluid Fractions from Patients with Suspected Invasive Pulmonary Fungal Disease. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	28
12	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole. <i>Mycoses</i> , 2018, 61, 868-876.	1.8	9
13	Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study. <i>International Journal of Drug Policy</i> , 2018, 59, 54-62.	1.6	6
14	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<scp>AGIHO</scp>). <i>Mycoses</i> , 2018, 61, 796-813.	1.8	69
15	Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 39-47.	0.7	5
16	Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1281-1292.	1.2	35
17	Medical diagnostics for indoor mold exposure. <i>International Journal of Hygiene and Environmental Health</i> , 2017, 220, 305-328.	2.1	58
18	Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3406-3413.	1.3	58

#	ARTICLE	IF	CITATIONS
19	Abridged version of the AWMF guideline for the medical clinical diagnostics of indoor mould exposure. <i>Allergo Journal International</i> , 2017, 26, 168-193.	0.9	16
20	33. Pilzinfektionen in der Gastroenterologie. , 2017, , .		0
21	Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive <i>Aspergillus</i> infections. <i>Mycoses</i> , 2016, 59, 480-493.	1.8	19
22	Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. <i>Medical Mycology</i> , 2016, 55, myw091.	0.3	13
23	Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. <i>Annals of Hematology</i> , 2016, 95, 1435-1455.	0.8	169
24	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet, The</i> , 2016, 387, 760-769.	6.3	695
25	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 828-837.	4.6	528
26	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2016, 174, 343-353.	1.9	20
27	Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. <i>Medical Mycology</i> , 2016, 54, 128-137.	0.3	17
28	Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. <i>Journal of Medical Microbiology</i> , 2016, 65, 1414-1421.	0.7	62
29	Clinical Performance of <i>Aspergillus</i> PCR for Testing Serum and Plasma: a Study by the European <i>Aspergillus</i> PCR Initiative. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2832-2837.	1.8	105
30	Combination Antifungal Therapy for Invasive Aspergillosis. <i>Annals of Internal Medicine</i> , 2015, 162, 81-89.	2.0	376
31	Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data. <i>AIDS Research and Therapy</i> , 2015, 12, 1.	0.7	20
32	HPLC method for the determination of the S- and R-diastereomers of telaprevir for treatment of patients with hepatitis C. <i>Laboratoriums Medizin</i> , 2015, 39, .	0.1	0
33	<i>Aspergillus</i> Specific PCR and Galactomannan of Bronchoalveolar Lavage Are Superior to Concomitant Same-Day Testing of Concurrent Blood Samples in Immunocompromised Hematological Patients with Suspected Invasive Aspergillosis. <i>Blood</i> , 2015, 126, 2072-2072.	0.6	0
34	Pharmacokinetic Analysis during Antifungal Prophylaxis with Posaconazole Suspension in Pediatric and Adolescent Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 4338-4338.	0.6	0
35	Treatment of invasive fungal infections in cancer patients – updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2014, 93, 13-32.	0.8	143
36	Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3610-3617.	1.4	79

#	ARTICLE	IF	CITATIONS
37	A Phase III, Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Isavuconazole Versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Hematopoietic Stem Cell Transplant Patients with Invasive Aspergillosis. <i>Blood</i> , 2014, 124, 1133-1133.	0.6	2
38	Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. <i>British Journal of Haematology</i> , 2013, 161, 517-524.	1.2	61
39	Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. <i>Haematologica</i> , 2013, 98, e127-e130.	1.7	99
40	Multicenter Comparison of Serum and Whole-Blood Specimens for Detection of Aspergillus DNA in High-Risk Hematological Patients. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1445-1450.	1.8	74
41	Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. <i>Mycoses</i> , 2013, 56, 304-310.	1.8	49
42	Investigation Of Fresh Tissue and Effusion Samples From Immunocompromised Hematologic Patients Suspected For Invasive Fungal Infection With An Aspergillus-specific PCR Is a Promising Tool For Identifying Invasive Aspergillosis. <i>Blood</i> , 2013, 122, 4552-4552.	0.6	0
43	Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction. <i>Current Medical Research and Opinion</i> , 2012, 28, 551-557.	0.9	7
44	Therapeutic drug monitoring of antifungal agents. <i>Laboratoriums Medizin</i> , 2012, 36, 1-10.	0.1	0
45	Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients with Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2652-2658.	1.4	39
46	A Novel Extraction Method Combining Plasma with a Whole-Blood Fraction Shows Excellent Sensitivity and Reproducibility for Patients at High Risk for Invasive Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2585-2591.	1.8	24
47	Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2260-2267.	1.3	85
48	Therapeutisches Drug Monitoring von Antimykotika/Therapeutic drug monitoring of antifungal agents. <i>Laboratoriums Medizin</i> , 2012, 36, .	0.1	0
49	Population Pharmacokinetics of Liposomal Amphotericin B and Caspofungin in Allogeneic Hematopoietic Stem Cell Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 536-543.	1.4	46
50	Epidemiology of <i>Candida</i> blood stream infections in patients with hematological malignancies or solid tumors. <i>Medical Mycology</i> , 2012, 50, 50-55.	0.3	57
51	Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation – guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2012, 91, 1161-1174.	0.8	40
52	Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. <i>European Journal of Haematology</i> , 2012, 89, 120-127.	1.1	63
53	Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. <i>Current Medical Research and Opinion</i> , 2011, 27, 335-342.	0.9	1
54	Diagnosis and therapy of <i>Candida</i> infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. <i>Mycoses</i> , 2011, 54, 279-310.	1.8	118

#	ARTICLE	IF	CITATIONS
55	High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 239-245.	1.1	34
56	Relevance of Timing for Determination of Posaconazole Plasma Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3621-3623.	1.4	17
57	Pathogen-Specific DNA Enrichment Does Not Increase Sensitivity of PCR for Diagnosis of Invasive Aspergillosis in Neutropenic Patients. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1267-1273.	1.8	39
58	Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. <i>Haematologica</i> , 2011, 96, 142-149.	1.7	99
59	Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4143-4149.	1.4	38
60	Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. <i>Haematologica</i> , 2009, 94, 113-122.	1.7	160
61	Cidofovir for BK Virus-associated Hemorrhagic Cystitis: A Retrospective Study. <i>Clinical Infectious Diseases</i> , 2009, 49, 233-240.	2.9	112
62	Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (ÄGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Annals of Hematology</i> , 2009, 88, 97-110.	0.8	128
63	Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. <i>European Journal of Cancer</i> , 2009, 45, 2462-2472.	1.3	115
64	Simultaneous Determination of Voriconazole and Posaconazole Concentrations in Human Plasma by High-Performance Liquid Chromatography. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3140-3142.	1.4	35
65	Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.. <i>Blood</i> , 2009, 114, 4736-4736.	0.6	0
66	PGA4, a GAS homologue from <i>Candida albicans</i> , is up-regulated early in infection processes. <i>Fungal Genetics and Biology</i> , 2007, 44, 368-377.	0.9	20
67	Primary antifungal prophylaxis in leukaemia patients. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 43-48.	2.2	57
68	Parathyroid-hormone-related-protein-associated hypercalcemia in a patient with CLL-type low-grade leukemic B-cell lymphoma. <i>Haematologica</i> , 2006, 91, ECR45.	1.7	7
69	Molecular responses to changes in the environmental pH are conserved between the fungal pathogens <i>Candida dubliniensis</i> and <i>Candida albicans</i> . <i>International Journal of Medical Microbiology</i> , 2000, 290, 231-238.	1.5	16
70	Rapid PCR Test for Discriminating between <i>Candida albicans</i> and <i>Candida dubliniensis</i> Isolates Using Primers Derived from the pH-Regulated PHR1 and PHR2 Genes of <i>C. albicans</i> . <i>Journal of Clinical Microbiology</i> , 1999, 37, 1587-1590.	1.8	75